Resting Energy Expenditure in Palliative Cancer Patients (REPAT) - an Explorative Study in Patients With Incurable Cancer
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 160
- Locations
- 2
- Primary Endpoint
- Measurement of resting energy expenditure (REE) in patients with incurable cancer measured with the COSMED Q-NRG+ Indirect Calorimeter with a Canopy Hood.
Study Overview
Brief Summary
The study purpose is to measure REE by indirect calorimetry and to determine limits of agreement with confidence intervals between measured REE and predictive equations for determination of energy requirements in patients with incurable cancer. Clinical factors associated with hyper- and hypometabolism will be elucidated. Data will be obtained from patient journals in combination with measurements of REE and registration of survival. Data will be collected at one timepoint and survival will be monitored prospectively.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •A verified diagnosis of an incurable malignant disease
- •Hospitalized at the Cancer clinic, St. Olavs Hospital
- •≥ 18 years of age
- •Able to provide written informed consent
- •Able to comply with all study procedures
Exclusion Criteria
- •Cognitive impairment
- •In need of supplementary oxygen
- •Receiving invasive or noninvasive ventilation
Outcomes
Primary Outcomes
Measurement of resting energy expenditure (REE) in patients with incurable cancer measured with the COSMED Q-NRG+ Indirect Calorimeter with a Canopy Hood.
Time Frame: Throughout study completion, approximately 3 years.
Investigate the agreement between the most used energy expenditure prediction equation (Harris-Benedict calculation for resting energy expenditure based on weight, height and gender) and measured REE (kilocalories/day) by indirect calorimetry in patients with incurable cancer.
Secondary Outcomes
- Clinical factors associated with hyper- and hypometabolism(Throughout study completion, approximately 3 years.)